Aleppo G, Beck RW, Bailey R, et al. - In patients with type 2 diabetes treated with basal insulin who had been utilizing real-time continuous glucose monitoring (CGM) for 8 months, stopping CGM resulted in a loss of approximately one-half of the initial gain in time in range (TIR) acquired while using CGM.

• This multicenter trial began with 8-month randomization to either real-time CGM or blood glucose monitoring (BGM), followed by a 6-month period during which the BGM group continued to use BGM (n = 57) and the CGM group was randomly assigned to either continue CGM (n = 53) or discontinue CGM with a resumption of BGM for glucose monitoring (n = 53).

• In the group that stopped CGM, mean TIR 70–180 mg/dL, which improved from 38% before starting CGM to 62% after 8 months of CGM, declined after stopping CGM to 50% at 14 months.

• TIR showed little improvement from 8 to 14 months in the group that continued to use CGM.

• When the two groups were compared at 14 months, the adjusted treatment group difference in mean TIR was −6%.